Despite near universal use of ursodeoxycholic acid (UDCA) several patients with PBC still
progress to liver transplant (LT) or death. Pruritus and fatigue are the most common …

Opinion statement Liver transplantation is an effective form of therapy for patients with end-
stage cholestatic disease that improves both survival and quality of life. Liver transplantation …

The recurrence of primary biliary cirrhosis (PBC) in the hepatic allograft may impact patient
and graft survival with long‐term follow‐up. The efficacy of ursodeoxycholic acid (UDCA) for …

Primary biliary cirrhosis (PBC) recurs after orthotopic liver transplantation (OLT) in up to one‐
third of patients. These patients are typically asymptomatic, can be identified by abnormal …

Background A decrease in the need for liver transplantations (LTX) in Primary Biliary
Cirrhosis (PBC), possibly related to treatment with ursodeoxycholic acid (UDCA), has been …

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) represent major
indications for liver transplantation (LT). Despite the steady increase in the incidence and …

Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease
characterized by progressive cholangiocyte and bile duct destruction leading to fibrosis and …

Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver, characterized by the
presence of antimitochondrial antibodies (AMA) and progressive immune-mediated …

Recurrent primary biliary cirrhosis (PBC) is an important clinical outcome after liver
transplantation (LT) in selected patients. Prevalence rates for recurrent PBC (rPBC) reported …

Background & Aims: Ursodeoxycholic acid (UDCA) has shown efficacy in primary biliary
cirrhosis (PBC), a chronic, slowly progressive disease. We hypothesized that UDCA use …